Cardiac Magnetic Resonance Imaging and Clinical Follow-up in Antimalarial-induced Cardiomyopathy in Patients With Systemic Lupus Erythematosus

J Thorac Imaging. 2023 May 1;38(3):W30-W32. doi: 10.1097/RTI.0000000000000694. Epub 2023 Jan 9.

Abstract

Antimalarial-induced cardiomyopathy is under-recognized in clinical practice and there is limited data on the evolution of cardiac imaging abnormalities after cessation of anti-malarial therapy. In this case series of 9 patients with antimalarial-induced cardiomyopathy, follow-up cardiac magnetic resonance imaging demonstrated interval increase in late gadolinium enhancement extent in 89% of patients and interval decrease in left ventricular ejection fraction in all, despite cessation of anti-malarial therapy. Progression of cardiac abnormalities despite cessation of therapy underscores the important role of imaging in the early recognition of antimalarial-related treatment changes.

MeSH terms

  • Antimalarials* / adverse effects
  • Cardiomyopathies* / chemically induced
  • Cardiomyopathies* / diagnostic imaging
  • Contrast Media / adverse effects
  • Follow-Up Studies
  • Gadolinium
  • Humans
  • Lupus Erythematosus, Systemic* / complications
  • Lupus Erythematosus, Systemic* / diagnostic imaging
  • Lupus Erythematosus, Systemic* / drug therapy
  • Magnetic Resonance Imaging
  • Magnetic Resonance Imaging, Cine
  • Predictive Value of Tests
  • Stroke Volume
  • Ventricular Function, Left

Substances

  • Antimalarials
  • Contrast Media
  • Gadolinium